Advanced Non-Squamous & Squamous NSCLC Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA By Delveinsight

(MENAFN- GetNews)

DelveInsight's,
“Advanced Non-Squamous & Squamous NSCLC Pipeline Insight, 2024,”
report provides comprehensive insights about
9+ companies and 11+ pipeline drugs
in Advanced Non-Squamous & Squamous NSCLC pipeline landscape. It covers the Advanced Non-Squamous & Squamous NSCLC pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Non-Squamous & Squamous NSCLC therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Advanced Non-Squamous & Squamous NSCLC Research. Learn more about our innovative pipeline today! @ Advanced Non-Squamous & Squamous NSCLC Pipeline Outlook

Key Takeaways from the Advanced Non-Squamous & Squamous NSCLC Pipeline Report

• June 2024:- Summit Therapeutics - A Randomized, Double-blind, Multi-center, Phase III Clinical Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Progressed on or Following Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment (HARMONi).
• June 2024:- AstraZeneca - The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.
• June 2024:- AbbVie - A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer.
• June 2024:- Arcus Biosciences Inc. - A Phase 3 Study to Evaluate Zimberelimab (AB122) Combined With AB154 in Front-Line, PD-L1-High, Locally Advanced or Metastatic Non-Small Cell Lung Cancer. This is a phase 3 study to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) compared to pembrolizumab in front-line, PD-L1-high, locally advanced or metastatic NSCLC.
• June 2024:- Genelux Corporation - A Randomized Phase 2 Study Assessing the Efficacy and Safety of Olvimulogene Nanivacirepvec Followed by Platinum-doublet Chemotherapy + Physician's Choice of Immune Checkpoint Inhibitor Compared With Docetaxel in Patients With NSCL Cancer After First Progression While on Front-line Immune Checkpoint Inhibitor-based Maintenance.
• June 2024:- Boehringer Ingelheim- Beamion LUNG 2: A Phase III, Open-label, Randomized, Active-controlled, Multi-centre Trial Evaluating Orally Administered Zongertinib (BI 1810631) Compared With Standard of Care as First-line Treatment in Patients With Unresectable, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Harbouring HER2 Tyrosine Kinase Domain Mutations.
• June 2024:- Mabscale LLC -BEV-III/2022 is a double-blind randomized multicenter clinical trial comparing efficacy of bevacizumab (manufactured by Mabscale, LLC) and paclitaxel plus carboplatin to Avastin® and paclitaxel plus carboplatin in first-line treatment for patients with advanced (unresectable, locally advanced, recurrent or metastatic) non-squamous NSCLC. The purpose of the study is to demonstrate equivalence of efficacy and safety of bevacizumab (manufactured by Mabscale, LLC) to Avastin®.
• DelveInsight's Advanced Non-Squamous & Squamous NSCLC pipeline report depicts a robust space with 9+ active players working to develop 11+ pipeline therapies for Advanced Non-Squamous & Squamous NSCLC treatment.
• The leading Advanced Non-Squamous & Squamous NSCLC Companies such as Jiangsu Alphamab Biopharmaceuticals, Jiangsu HengRui Medicine, Novartis Pharmaceuticals, Genentech, and others.
• Promising Advanced Non-Squamous & Squamous NSCLC Therapies such as Pembrolizumab, Bevacizumab, Pemetrexed, RBN-2397, Tiragolumab, Pyrotinib, Docetaxel, SAR408701 (Tusamitamab ravtansine) , and others.

Stay informed about the cutting-edge advancements in Advanced Non-Squamous & Squamous NSCLC Treatments. Download for updates and be a part of the revolution in cancer care @ Advanced Non-Squamous & Squamous NSCLC Clinical Trials Assessment

Advanced Non-Squamous & Squamous NSCLC Emerging Drugs Profile

• Erfonrilimab: Jiangsu Alphamab Biopharmaceuticals

KN-046 (Erfonrilimab) is a bispecific antibody targeting both programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). The drug is currently being evaluated under the Phase III clinical trial for the treatment of Advanced Squamous Non-small Cell Lung Cancer.

• Pyrotinib: Jiangsu HengRui Medicine

Pyrotinib is an irreversible dual pan-ErbB receptor tyrosine kinase inhibitor developed for the treatment of HER2-positive advanced solid tumours. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients suffering from advanced non-squamous NSCLC.

Learn more about Advanced Non-Squamous & Squamous NSCLC Drugs opportunities in our groundbreaking Advanced Non-Squamous & Squamous NSCLC Research and development projects @ Advanced Non-Squamous & Squamous NSCLC Unmet Needs

Advanced Non-Squamous & Squamous NSCLC pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Oral
• Subcutaneous
• Intravitreal
• Intramuscular

Advanced Non-Squamous & Squamous NSCLC Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Discover the latest advancements in Advanced Non-Squamous & Squamous NSCLC Treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ Advanced Non-Squamous & Squamous NSCLC Market Drivers and Barriers, and Future Perspectives

Advanced Non-Squamous & Squamous NSCLC Companies and Drugs

• Ribon Therapeutics Inc.: RBN-2397
• Summit Therapeutics:- AK112 Injection
• Jiangsu HengRui Medicine Co., Ltd.:- Pyrotinib/Docetaxel
• Sanofi:- SAR408701 (Tusamitamab ravtansine)
• Shanghai Shengdi Pharmaceutical Co., Ltd:- Adebrelimab+SHR-8068+Pemetrexed+Carboplatin

Scope of the Advanced Non-Squamous & Squamous NSCLC Pipeline Report

• Coverage- Global
• Advanced Non-Squamous & Squamous NSCLC Companies- Jiangsu Alphamab Biopharmaceuticals, Jiangsu HengRui Medicine, Novartis Pharmaceuticals, Genentech, and others.
• Advanced Non-Squamous & Squamous NSCLC Therapies- Pembrolizumab, Bevacizumab, Pemetrexed, RBN-2397, Tiragolumab, Pyrotinib, Docetaxel, SAR408701 (Tusamitamab ravtansine), and others.
• Advanced Non-Squamous & Squamous NSCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Advanced Non-Squamous & Squamous NSCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Advanced Non-Squamous & Squamous NSCLC Pipeline on our website @ Advanced Non-Squamous & Squamous NSCLC Drugs and Companies

Table of Content